Pulmonx Corp
$ 1.47
0.68%
17 Apr - close price
- Market Cap 62,089,000 USD
- Current Price $ 1.47
- High / Low $ 1.53 / 1.46
- Stock P/E N/A
- Book Value 1.30
- EPS -1.33
- Next Earning Report 2026-04-29
- Dividend Per Share N/A
- Dividend Yield 0 %
- Next Dividend Date -
- ROA -0.23 %
- ROE -0.77 %
- 52 Week High 5.46
- 52 Week Low 1.13
About
Pulmonx Corporation, a medical technology company, designs, develops, manufactures and markets minimally invasive medical devices for the diagnosis and treatment of chronic obstructive pulmonary diseases. The company is headquartered in Redwood City, California.
Analyst Target Price
$5.17
Quarterly Earnings
| Dec 2025 | Sep 2025 | Jun 2025 | Mar 2025 | Dec 2024 | Sep 2024 | Jun 2024 | Mar 2024 | Dec 2023 | Sep 2023 | Jun 2023 | Mar 2023 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Reported Date | 2026-02-25 | 2025-11-12 | 2025-07-29 | 2025-04-29 | 2025-02-19 | 2024-10-30 | 2024-07-31 | 2024-05-01 | 2024-02-21 | 2023-10-30 | 2023-08-02 | 2023-05-02 |
| Reported EPS | -0.25 | -0.34 | -0.38 | -0.36 | -0.33 | -0.36 | -0.35 | -0.36 | -0.36 | -0.39 | -0.43 | -0.42 |
| Estimated EPS | -0.3948 | -0.42 | -0.3943 | -0.3952 | -0.45 | -0.45 | -0.43 | -0.46 | -0.41 | -0.43 | -0.44 | -0.44 |
| Surprise | 0.1448 | 0.08 | 0.0143 | 0.0352 | 0.12 | 0.09 | 0.08 | 0.1 | 0.05 | 0.04 | 0.01 | 0.02 |
| Surprise Percentage | 36.6768% | 19.0476% | 3.6267% | 8.9069% | 26.6667% | 20% | 18.6047% | 21.7391% | 12.1951% | 9.3023% | 2.2727% | 4.5455% |
Next Quarterly Earnings
| Mar 2026 | |
|---|---|
| Reported Date | 2026-04-29 |
| Fiscal Date Ending | 2026-03-31 |
| Estimated EPS | -0.33 |
| Currency | USD |
Next Dividend Records
| Dividend per share (year): | - |
| Dividend Yield | - |
| Next Dividend Date | - |
| Ex-Dividend Date | - |
Recent News: LUNG
2026-04-19 14:40:17
Pulmonx's investment narrative is re-centering around a lower US$5 price target, despite its fair value estimate remaining at US$5.17 per share. Bullish analysts view this as a more attainable goal, while bearish commentators see it as a sign of reduced near-term expectations and persistent execution risks. The company issued 2026 revenue guidance between US$90-US$92 million, with its intrinsic value model remaining largely unchanged.
2026-04-15 20:10:33
Pulmonx (Nasdaq: LUNG) announced it will release its first quarter 2026 financial results on Wednesday, April 29, 2026, after market close. Following the release, the company will host a conference call at 1:30 p.m. PT / 4:30 p.m. ET to discuss the results, with a live and archived webcast available on its Investors website. The announcement follows a pattern from previous earnings reports that have positively impacted stock movement.
2026-04-13 15:10:17
Pulmonx Corp, a medtech company, specializes in providing innovative, minimally invasive lung devices, specifically Zephyr Valves, for treating severe emphysema. The article highlights Pulmonx's strong position in the U.S. market, supported by clinical evidence, FDA approval, and Medicare reimbursement, catering to a significant unmet need in COPD treatment. While acknowledging potential risks such as physician training challenges and reimbursement changes, the article suggests that the company's focus on a niche market and robust clinical data could drive sustained growth for investors.
2026-04-13 14:39:15
Pulmonx Corp (LUNG) specializes in minimally invasive devices, like the Zephyr Endoluminal Valve System, for treating severe emphysema. The company targets the growing COPD market, particularly in the U.S. with established Medicare reimbursement, leveraging strong clinical evidence and a focus on expanding treatment centers. While analysts are optimistic about its growth potential, investors should monitor procedure adoption rates, international expansion, and the company's cash burn.
2026-04-06 03:40:20
Insiders at Pulmonx Corporation sold US$371k worth of stock in the past year, which was a beneficial move as the stock price has since fallen below their average selling price of US$1.84. Recent significant insider selling of US$141k in the last three months, with no purchases, raises caution among investors. While insiders own 5.2% of the company, this figure is not considered impressive, leading to a cautious outlook on the stock.
2026-03-27 16:08:49
The Vanguard Group has filed an amended Schedule 13G/A, reporting zero beneficial ownership of Pulmonx Corp Common Stock (LUNG). This change, effective January 12, 2026, is due to an internal realignment under SEC Release No. 34-39538, which now requires certain Vanguard subsidiaries to report their holdings separately. The filing confirms Vanguard itself no longer holds beneficial ownership in Pulmonx.
